Jun 04, 2024
Acquisition of Fusion Pharmaceuticals Completed
May 31, 2024
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
May 09, 2024
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
May 07, 2024
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
Apr 25, 2024
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
Apr 09, 2024
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
Mar 20, 2024
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
Mar 19, 2024
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
Mar 06, 2024
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 05, 2024
Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting
Feb 26, 2024
Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences
Feb 16, 2024
Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy
Feb 07, 2024
Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Jan 04, 2024
Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates